G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping reviewKim Campbell, Edward Li, Weijia Wang et al.|Expert Review of Hematology|2022Cited by 14
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysisAli McBride, Weijia Wang, Kim Campbell et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 11
The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data AnalysisEdward Li, Weijia Wang, Bridgette Kanz Schroader et al.|Journal of health economics and outcomes research|2021Cited by 2
HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018Weijia Wang, Ali McBride, Edward Li et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1
The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data AnalysisEdward Li, Weijia Wang, David L. Campbell et al.|Journal of health economics and outcomes research|2021Cited by 1